Short-term Variations in Bodily Pain and Related Baseline Characteristics in Fibromyalgia Patients Undergoing Paraprobiotic Supplementation: A Retrospective Observational Analysis - Report - MDSpire

Short-term Variations in Bodily Pain and Related Baseline Characteristics in Fibromyalgia Patients Undergoing Paraprobiotic Supplementation: A Retrospective Observational Analysis

  • By

  • David Castro Corredor

  • Luis Ángel Calvo Pascual

  • María B. García-Moreno García

  • April 24, 2026

  • 0 min

Share

Short-term Variations in Bodily Pain in Fibromyalgia Patients

Overview

This study assessed the impact of paraprobiotic supplementation on bodily pain in fibromyalgia patients over two months. Results indicated significant improvement in bodily pain scores at two months, with dyslipidemia identified as a key factor associated with lower pain scores.

Background

Fibromyalgia is a chronic pain syndrome that significantly affects quality of life, characterized by widespread pain and various comorbid symptoms. Understanding the factors influencing pain trajectories is crucial for developing effective management strategies. This study explores the role of paraprobiotics in modifying pain outcomes in fibromyalgia patients, providing insights into potential therapeutic avenues.

Data Highlights

Time PointBodily Pain Score Change (β)95% CIp-value
Baseline to T11.92−0.39 to 4.230.103
Baseline to T26.953.12 to 10.78<0.001
T1 to T25.031.45 to 8.600.006

Key Findings

  • Significant improvement in bodily pain scores was observed at T2 compared to baseline.
  • Dyslipidemia was independently associated with lower bodily pain scores.
  • Smoking status showed a weaker borderline association with pain scores.
  • Results were consistent across various analytical approaches, including sensitivity analyses.
  • The study highlights the need for further research on metabolic factors in fibromyalgia management.

Clinical Implications

Clinicians should consider the role of dyslipidemia in fibromyalgia patients, as it may influence pain outcomes. The findings suggest that paraprobiotic supplementation could be a potential adjunctive therapy, warranting further investigation in controlled studies.

Conclusion

This exploratory study indicates that paraprobiotic supplementation may improve bodily pain in fibromyalgia patients, particularly over a two-month period. Further research is needed to confirm these findings and explore the underlying mechanisms.

References

  1. Author(s)/Org, Source, Year -- Proinflammatory diet is associated with higher pain, disease severity and biochemical parameters associated with inflammation in fibromyalgia
  2. Author(s)/Org, Source, Year -- Analysis of Clinical Outcomes from Medicinal Cannabis Treatment for Fibromyalgia: Insights from the UK Medical Cannabis Registry
  3. Author(s)/Org, Source, Year -- Aftersensations and Lingering Pain After Examination in Patients with Fibromyalgia Syndrome
  4. EULAR revised recommendations for the management of fibromyalgia | Annals of the Rheumatic Diseases
  5. European Radiology — Assessment of Lumbar Paraspinal Muscle Quality in Chronic Low Back Pain Patients: Correlations with Pain Duration, Intensity, and Quality of Life
  6. The gut microbiota promotes pain in fibromyalgia
  7. Physical activity should be the primary intervention for individuals living with chronic pain
  8. EULAR revised recommendations for the management of fibromyalgia | Annals of the Rheumatic Diseases

Original Source(s)

Related Content